These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 22251978

  • 1. Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
    Parry PV, Engh JA.
    Neurosurgery; 2012 Feb; 70(2):N10-1. PubMed ID: 22251978
    [No Abstract] [Full Text] [Related]

  • 2. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Hirano T.
    Circ J; 2014 Feb; 78(6):1317-9. PubMed ID: 24805358
    [No Abstract] [Full Text] [Related]

  • 3. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 4. Intracranial hemorrhage during dabigatran treatment.
    Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, Kameda K, Shono T, Nagata S, Ago T, Kitazono T, Okada Y.
    Circ J; 2014 Jul; 78(6):1335-41. PubMed ID: 24662438
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran and postmarketing reports of bleeding.
    Southworth MR, Reichman ME, Unger EF.
    N Engl J Med; 2013 Apr 04; 368(14):1272-4. PubMed ID: 23484796
    [No Abstract] [Full Text] [Related]

  • 6. Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature.
    Wassef SN, Abel TJ, Grossbach A, Viljoen SV, Jackson AW, Howard MA, Greenlee JD.
    Neurosurgery; 2013 Aug 04; 73(2):E368-73; discussion E373-4. PubMed ID: 23670031
    [Abstract] [Full Text] [Related]

  • 7. Plasma dabigatran activity one week after discontinuation despite normal renal function.
    Thachil J, Pike G, Keighley-Jones L, Nash MJ.
    Am J Med; 2013 Aug 04; 126(8):e5-6. PubMed ID: 23800582
    [No Abstract] [Full Text] [Related]

  • 8. Dabigatran-induced acute hepatitis.
    Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A.
    Clin Appl Thromb Hemost; 2012 Sep 04; 18(5):549-50. PubMed ID: 22962308
    [No Abstract] [Full Text] [Related]

  • 9. Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
    Aron JL, Gosselin R, Moll S, Arkin CF, Mantha S.
    J Thromb Thrombolysis; 2014 Sep 04; 37(2):76-9. PubMed ID: 23519385
    [No Abstract] [Full Text] [Related]

  • 10. [Advantages of NOAKs validated in clinical routine].
    Ameri AA.
    MMW Fortschr Med; 2015 May 13; 157(9):70. PubMed ID: 26012835
    [No Abstract] [Full Text] [Related]

  • 11. [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
    MMW Fortschr Med; 2012 Jan 19; 154(1):20. PubMed ID: 22641998
    [No Abstract] [Full Text] [Related]

  • 12. Dabigatran in patients with nonvalvular atrial fibrillation.
    Gage L.
    J Am Coll Cardiol; 2011 Jul 26; 58(5):551; author reply 551. PubMed ID: 21777759
    [No Abstract] [Full Text] [Related]

  • 13. Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
    Bendel SD, Bona R, Baker WL.
    Adv Ther; 2011 Jun 26; 28(6):460-72. PubMed ID: 21533567
    [Abstract] [Full Text] [Related]

  • 14. Removal of dabigatran by hemodialysis.
    Chang DN, Dager WE, Chin AI.
    Am J Kidney Dis; 2013 Mar 26; 61(3):487-9. PubMed ID: 23219111
    [Abstract] [Full Text] [Related]

  • 15. Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
    Pollack CV, Levy JH, Eikelboom J, Weitz JI, Sellke FW, Huisman MV, Steiner T, Kamphuisen P, Bernstein RA.
    Am J Emerg Med; 2014 Nov 26; 32(11):1433-4. PubMed ID: 25239691
    [No Abstract] [Full Text] [Related]

  • 16. Bleeding risk with dabigatran in the frail elderly.
    Harper P, Young L, Merriman E.
    N Engl J Med; 2012 Mar 01; 366(9):864-6. PubMed ID: 22375994
    [No Abstract] [Full Text] [Related]

  • 17. Diffuse alveolar hemorrhage associated with dabigatran.
    Yokoi K, Isoda K, Kimura T, Adachi T.
    Intern Med; 2012 Mar 01; 51(18):2667-8. PubMed ID: 22989848
    [No Abstract] [Full Text] [Related]

  • 18. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.
    Circulation; 2011 May 31; 123(21):2363-72. PubMed ID: 21576658
    [Abstract] [Full Text] [Related]

  • 19. [Dabigatran and emergency operation on a peritonitis patient].
    Ilmakunnas M, Louhimo J, Lassila R.
    Duodecim; 2012 May 31; 128(7):753-7. PubMed ID: 22612026
    [Abstract] [Full Text] [Related]

  • 20. Dabigatran overdose secondary to acute kidney injury and amiodarone use.
    Fountzilas C, George J, Levine R.
    N Z Med J; 2013 Mar 01; 126(1370):110-2. PubMed ID: 23474519
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.